In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective α1A receptor antagonists for the treatment of benign prostatic hyperplasia

…, KL Glass, KE Rittle, KF Gilbert, TG Steele…

Index: Steele, Thomas G.; Coburn, Craig A.; Patane, Michael A.; Bock, Mark G. Tetrahedron Letters, 1998 , vol. 39, # 51 p. 9315 - 9318

Full Text: HTML

Citation Number: 195

Abstract

α1 Adrenergic receptors mediate both vascular and lower urinary tract tone, and α1 receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified,

Related Articles:

Microwave-assisted solution phase synthesis of dihydropyrimidine C5 amides and esters

[Desai, Bimbisar; Dallinger, Doris; Kappe, C. Oliver Tetrahedron, 2006 , vol. 62, # 19 p. 4651 - 4664]

Solid-phase synthesis of dihydropyrimidones via N-acyliminium ion-based α-ureidoalkylations

[Valverde, Maria Garcia; Dallinger, Doris; Kappe, C. Oliver Synlett, 2001 , # 6 p. 741 - 744]

Synthesis and Evaluation of 3, 4??Dihydropyrimidin??2 (1H)??ones as Sodium Iodide Symporter Inhibitors

[Lacotte, Pierre; Puente, Celine; Ambroise, Yves ChemMedChem, 2013 , vol. 8, # 1 p. 104 - 111]

Solid-phase synthesis of dihydropyrimidones via N-acyliminium ion-based α-ureidoalkylations

[Valverde, Maria Garcia; Dallinger, Doris; Kappe, C. Oliver Synlett, 2001 , # 6 p. 741 - 744]

More Articles...